| Status: Under consideration by AWMSG Scrutiny Panel | |
For the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages. Scrutiny panel considered progesterone (Prometrium®) was suitable for a limited assessment. |
|
Medicine details |
|
| Medicine name | progesterone (Prometrium®) |
| Formulation | 400 mg vaginal capsules |
| Reference number | 6820 |
| Indication | As above |
| Company | Besins Healthcare UK Ltd |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 07/08/2025 |
| Further information Prometrium® is suitable for a limited assessment via the Licensed Medicines One Wales Medicines Assessment Group (LOWMAG). This is the first licensed progesterone product for this patient group and will replace off-label preparations used in NHS Wales. There is national clinical guidance from NICE and the Royal College of Obstetrics and Gynaecology available recommending use of progesterone products for this indication. The clinical effectiveness and cost-effectiveness have been sufficiently established from published clinical and economic studies according to NICE in the development of their guidelines. |
|